Japan Debuts Novel Dry Eye Therapy

Senju Pharmaceutical launches the first TRPV1 antagonist for dry eye in Japan

April 30, 2026
3 min

The Ophthalmologist

Share

Senju Pharma has introduced Avarept (motugivatrep), the world's first dry eye therapy targeting the TRPV1 antagonist class, in Japan. This innovative treatment aims to address the growing prevalence of dry eye disease (DED), impacting over 20 million individuals, especially among the aging population. Traditional therapies often provide inadequate relief, making Avarept a crucial advancement in managing symptoms such as inflammation and discomfort. Backed by a successful clinical trial, Avarept represents a significant breakthrough in ophthalmic care, enhancing therapeutic options for clinicians and patients alike.